Figure 11.

Protein levels of N-Cadherin (a), ZEB-1 (b), Vimentin (c), β-Catenin (c) and Claudin (d) in both CSC populations treated for two or five weeks. HTLA-CSCs and ER-CSCs were treated three times a week with 0.1 µM C2-4, with 5 µM SSZ or with 1.25 µM Etoposide, administered once a week alone or in combination with C2-4 or SSZ. Immunoblots shown are representative of three independent experiments. To ensure normalized protein content all filters were stained with Red Ponceau. Bar graph summarizes quantitative data of means ± S.E.M. of three independent experiments. ** p < 0.01 vs. untreated CSCs (Ctr); *** p < 0.001 vs. untreated CSCs (Ctr); °° p < 0.01 vs. Etoposide-treated CSCs; °°° p < 0.001 vs. Etoposide-treated CSCs.